p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

OBJECTIVE Despite the clinical similarities triple-negative and basal-like breast cancer are not synonymous. Indeed, not all basal-like cancers are negative for estrogen receptor, progesterone receptor and HER2 expression while triple-negative also encompasses other cancer types. P53 protein appears heterogeneously expressed in triple-negative breast cancers, suggesting that it may be associated with specific biological subgroups with a different outcome. METHODS We comparatively analyzed p53 expression in triple-negative tumors from two independent breast cancer case series (633 cases from the University of Ferrara and 1076 cases from the University of Nottingham). RESULTS In both case series, p53 protein expression was able to subdivide the triple-negative cases into two distinct subsets consistent with a different outcome. In fact, triple-negative patients with a p53 expressing tumor showed worse overall and event-free survival. CONCLUSIONS The immunohistochemical evaluation of p53 expression may help in taming the currently stormy relationship between pathological (triple-negative tumors) and biological (basal breast cancers) classifications and in selecting patient subgroups with different biological features providing a potentially powerful prognostic contribution in triple-negative breast cancers.

[1]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[2]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[3]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[4]  Elia Biganzoli,et al.  Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods , 2006, Clinical Cancer Research.

[5]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[7]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Hirohashi,et al.  Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer , 1994, International journal of cancer.

[9]  S. Bull,et al.  Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer , 2007, Breast Cancer Research and Treatment.

[10]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[13]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[14]  C. Sotiriou,et al.  p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[16]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[17]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[18]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[19]  J. Stec,et al.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[21]  S. Chanock,et al.  Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status , 2008, Clinical Cancer Research.

[22]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[23]  Elia Biganzoli,et al.  Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers , 2009, BMC Bioinformatics.

[24]  Therese Sørlie,et al.  Introducing molecular subtyping of breast cancer into the clinic? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[26]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[27]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[28]  Donald Berry,et al.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.

[29]  J. Robins,et al.  A Structural Approach to Selection Bias , 2004, Epidemiology.

[30]  S. Parodi,et al.  Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. , 2004, Biochimica et biophysica acta.

[31]  Paulo J. G. Lisboa,et al.  A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients , 2010, Comput. Biol. Medicine.

[32]  S. Shousha,et al.  Oestrogen receptor status of breast carcinoma: Allred/H score conversion table , 2008, Histopathology.

[33]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Ahwon Lee,et al.  p53 as a specific prognostic factor in triple-negative breast cancer. , 2009, Japanese journal of clinical oncology.

[35]  Thierry Gil,et al.  Molecular targeted therapies in breast cancer: where are we now? , 2007, The international journal of biochemistry & cell biology.